Research Article

Tanshinone IIA Alleviates Traumatic Brain Injury by Reducing Ischemia–Reperfusion via the miR-124-5p/FoxO1 Axis

Wenbing Su,1 Meifen Lv,1 Dayu Wang,1 Yinghong He,1 Hui Han,1 Yu Zhang,1 Xiuying Zhang,1 Shaokun Lv,1 and Liqing Yao2

1Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China
2Department of Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China

Correspondence should be addressed to Shaokun Lv; qujinglvshaokun@163.com and Liqing Yao; yaoliqing98731@163.com

Received 18 July 2022; Revised 22 February 2023; Accepted 27 November 2023; Published 21 March 2024

Copyright © 2024 Wenbing Su et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Every year, more than 40-million cases of disability are caused by the cerebral vascular rupture, ischemia, or stroke worldwide [1]. Currently, the leading cause of disability in adults is ischemic stroke, for which the primary treatment is the immediate restoration of blood supply [2]. However, this may exacerbate brain damage caused by ischemia–reperfusion injury [3]. Worldwide, cerebral ischemia–reperfusion injury (CIRI) is an important cause of stroke death, damaging human
health, and inducing a heavy economic burden on society [4].
CIRI is a condition that occurs after surgery for cerebral ath-
erosclerosis and cerebral ischemia, is particularly common in
patients who have undergone arterial or intravenous throm-
bolysis and is characterized by high morbidity, mortality, and
recurrence [5]. Primary injury during ischemia and secondary
injury during reperfusion are the pathological processes of
CIRI, and the mechanism of injury is very complex [6–8].
However, the molecular mechanisms of the formation of cere-
bral ischemia–reperfusion injury are still unclear.

Salvia miltiorrhiza is a well-known traditional Chinese
herb that has been used clinically for more than 1,000 years.
It is extensively used to treat cardiovascular diseases and has
latent beneficial effects on chronic renal failure, hepatitis and
Alzheimer’s disease [9]. The lipid-soluble diterpene Tan-
shinone IIA can be isolated from Salvia miltiorrhiza and is the
major functional component of Salvia miltiorrhiza. Various
pharmacological functions have been found, such as prevent-
ing atherosclerosis, protecting the heart, inhibiting platelet
accumulation, and antitumor effects [10–13]. Several studies
have indicated that Tanshinone IIA alleviates cerebral ische-
mic injury [14, 15]. Several studies have demonstrated the
potential protective effect of Tanshinone IIA on preventing
cerebral ischemia–reperfusion injury [16]. For example, Tan-
shinone IIA ameliorated cognitive defects by inhibiting endo-
plasmic reticulum stress-induced apoptosis in APP/PS1
transgenic mice [17]. Tanshinone IIA sodium sulfate al-
leviated cardiac injury by modulating the system of oxidation
resistance, inflammation and fast dysfunction in atheroscle-
rosis [18]. However, the specific mechanism by which Tan-
shinone IIA alleviates cerebral ischemia–reperfusion injury
needs to be further investigated in depth.

Gene therapy has emerged as a potential therapeutic
option for ischemic stroke. MicroRNAs (miRNAs) are non-
coding small RNAs that target the 3’UTR of mRNAs to
degrade mRNAs and thus participate in various pathophysi-
ological processes [19]. As key regulators of many cellular
biological processes, miRNAs are widely expressed in the
central nervous system and are involved in the cell prolifera-
tion, apoptosis, and cell scorching [20]. MiR-124 is by far the
most common miRNA found in neurons. miR-124 has been
reported to be involved in regulating the polarity of activated
microglia and the shift in macrophages to the anti-inflammatory
M2 phenotype [21]. Early expression of miR-124 inhibits reac-
tive astrocytes to reduce ischemic core formation [22].

miRNAs can participate in various pathophysiological
processes after cerebral ischemia by regulating the mRNA
of target genes [23, 24]. Forkhead transcription factor O1
(FoxO1), one of the FOX family members, is expressed in
neurons, heart, and muscle and can bind to miRNAs to
regulate their stability and translation. The previous study
of target genes [23, 24]. Forkhead transcription factor O1,
(12 mg/kg) group. Tanshinone IIA (cat. no. HY-N0135) was
injected to the left (2), falling to the left (3), incapability to walk by
(0), incomplete extension of the right front paw (1), turning
scored by the Longa scoring system [28] as follows: normal
water content (%) = (wet weight–dry weight)/wet weight × 100%.

2. Materials and Methods

2.1. Establishment of a Cerebral Ischemia–Reperfusion Model. Healthy SD rats (250–300 g) were purchased from the Hunan
Slack Jingda Laboratory Animal Co., Ltd. All animal experi-
ments were carried out according to the Guide for the Care
and Use of Experimental Animals and were authorized by the
Ethics Committee of Hunan Provincial People’s Hospital. In
this study, a short-term middle cerebral artery occlusion-
reperfusion (MCAO/R) model was established [27]. To put
it simply, after the rats were anesthetized by an intraperitoneal
injection of sodium pentobarbital, an incision was made in the
middle of the neck, and the tissue was separated layer by layer
to expose and dissociate the right common carotid artery,
internal carotid artery, and external carotid artery. A small
incision was made in the external carotid artery near the heart,
through which sutures were inserted into the common carotid
artery, and then retrieved through the bifurcation of the com-
mon carotid artery into the internal carotid artery. After that,
the suture was slowly delivered to the origin of the middle
cerebral artery and inserted about 8.0 ± 0.5cm from the bifur-
cation of the common carotid artery. Finally, sutures were
secured and the skin of the neck was closed. In Sham oper-
ation group, only blood vessels were removed. After 24 hr of
reperfusion, neurological function was scored. Brain tissue
was used for the subsequent experiments.

2.2. Treatments. The male SD rats in each group were randomly divided into the following groups (n = 20/group): (1) model group; (2) Sham-operated group; (3) MCAO/R + Tanshinone IIA (4 mg/kg) group; (4) MCAO/R + Tanshinone IIA (8 mg/kg) group; and (5) MCAO/R + Tanshinone IIA (12 mg/kg) group. Tanshinone IIA (cat. no. HY-N0135) was purchased from MedChemExpress LLC (Monmouth Junction, NJ, USA). After 10 min of cerebral ischemia, the drug was administered by caudal vein injection, and after reperfu-
sion, the drug was injected again.

2.3. Neurological Function Score Assessment. After 24 hr of
ischemia–reperfusion, the neurological deficits of rats were
scored by the Longa scoring system [28] as follows: normal
(0), incomplete extension of the right front paw (1), turning
to the left (2), falling to the left (3), incapability to walk by
themselves, and low level of self-awareness (4).

2.4. Measurement of Brain Water Content. Twenty-four
hours after reperfusion, the wet weight of the brain was
determined. Then, the brain was dried at 105°C for 24 hr,
and the dry weight was recorded. Brain water content (%
(wet weight–dry weight)/wet weight × 100%.

2.5. Nissl Staining. Paraffin-embedded brain tissue sections
were routinely dewaxed and stained with Nissl solution
Mediators of Inflammation

(E607316, Sangon Biotech, Shanghai, China). Subsequently, the sections were rinsed and stained, dehydrated with ethanol, and sealed with neutral gum for observation and analysis.

2.6. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Staining. PBS was used to wash the brain tissue. Ethanol was used to dehydrate the tissues to prepare clear, waxed, and embedded sections. Dewaxing and double-distilled water treatment were performed. The samples were sealed after the TUNEL reaction solution was added and were photographed by a fluorescence microscopy. The number of TUNEL-positive cells was observed.

2.7. Tetrazolium Chloride (TTC) Staining. Twenty-four hours after the operation, the animals were deeply anesthetized by an intraperitoneal injection of pentobarbital sodium (40 mg/kg), and brain sections were immersed in TTC solution for 10 min at 37°C. After being stained, the normal tissues were dyed red, while the blocked tissues were dyed white. In addition, the infarct volumes were observed, and the infarct rates were calculated by an Image-Pro Plus 6.0.

2.8. Establishment of an In Vitro Oxygen Glucose Deprivation/Reoxygenation (OGD/R) Cell Model. As previously described by Liu et al. [27], 18-day-old embryos from the pregnant SD rats were used to isolate primary cortical neurons. Primary cortical neurons were cultured in a neural basal medium. Primary cortical neuronal cells were stimulated with OGD to establish a cerebral ischemia in vitro model. Before the OGD/R test, the cells were incubated with Tanshionone IIA (5, 10 or 15 μM) for 30 min. After being resuspended in DMEM (Gibco, Sangon Biotech, Shanghai, China), the cells were transferred to an oxygen deficit well and cultured in a gas mixture of 94% N2 and 5% CO2. Then, the neuronal cells were incubated in a normoxic incubator.

2.9. 3-[4,5-Dimethylthiazol-2-Yl]-2,5-Diphenyl Tetrazolium Bromide (MTT) Measurement. Cell activity was detected by the MTT assays. Primary cultured cortical neurons were inoculated in 96-well plates at a density of 1 × 104 neurons per well and treated with OGD/R. In addition, MTT solution was added, and the insoluble formazan crystals were collected and dissolved in the dimethyl sulfoxide (DMSO) at 37°C for 4 hr. After the crystals were fully dissolved, the OD570 value was measured by modulating the enzyme label. The experiment was repeated three times independently.

2.10. Lactate Dehydrogenase (LDH) Assay to Assess Cell Damage. The levels of LDH release in cultured cell supernatants were measured using an LDH assay kit (Beyotime). Primary cultured cortical neuronal cells were inoculated into 96-well plates for LDH activity analysis. LDH reaction solution (100 μL) was added and incubated for 30 min, and the OD value was assessed at 490 nm by a spectrophotometer (Epoch, USA).

2.11. Enzyme-Linked Immunosorbent Assay (ELISA). The levels of TNF-α, IL-6, and IL-1β were quantified using ELISA kits (TNF-α, ab245059, Abcam; IL-6, ab259381, Abcam; IL-1β, KE10003, Proteintech). The sample was added to the well, biotin-labeled antibody was added, and the cells were incubated at 37°C for 2 hr. Then, horseradish peroxidase-labeled streptavidin was added and incubated. Finally, the chromogenic solution was added for 0.5 hr. The reaction was terminated, and the OD value was measured at 450 nm.

2.12. Cell Transfection. Control miRNA (5'-UUCUCCG AACGUGUACGUTT-3’), the miR-124-5p mimic (5'-CGUUGUCACAGGGAACCUUGAU-3’), and the miR-124-5p inhibitor (5'-UCAAGGUCGUGUACAGC-3’) purchased from Sangon (Shanghai, China) and transfected into the neuronal cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Forty-eight hours after transfection, neuronal cells are collected for the subsequent experiments.

2.13. Flow Cytometry. As previously described by Wang et al. [29], flow cytometry was used to measure apoptosis. In addition, the cells were incubated in an Annexin V plus fluorescein isothiocyanate/propidium iodide kit, and then Annexin V and PI fluorescence were determined at the referenced emission wavelengths by a Beckman cytometer (BD Biosciences) and FlowJo software (V11).

2.14. Reverse TranscriptionQuantitative Polymerase Chain Reaction (RT–qPCR). In this study, we extracted total RNA from tissues and cells using a Total RNA Extractor (Sangon Biotech). A cDNA synthesis kit (Vazyme, Nanjing, China) was used to reverse transcribe 2 μg of RNA into cDNA, which was then diluted 10 times. One microliter of the prepared cDNA was used for qPCR. All primers (Table 1) used in this study were designed with Premier 5.0. The confidence of the qPCR results was assessed by the dissociation curve and cycle threshold (CT) values. The results were calculated by the 2^-ΔΔCt method and repeated at least three times.

2.15. Western Blotting. In this study, the proteins were extracted, and a BCA assay (Sangon Biotech, Shanghai) was used to determine the total protein content. A 10% SDS–PAGE gel was used to separate the total proteins, which were then transferred to PVDF membranes by a constant current flow at 200 mA. Subsequently, the PVDF membranes were incubated with Bax, Bcl-2, and Cleaved-caspase-3 antibodies (Abcam, USA) for 12 hr at 4°C. The PVDF membranes were washed with TBS buffer and incubated with secondary antibodies (Abcam) at 25°C for 1 hr. After the membranes were washed three times, chemiluminescent reagents were added, and the grayscale values of the bands were analyzed using ImageJ software. Each experiment was repeated three times independently.

2.16. Dual Luciferase Reporter Gene Assay. The selected vector (Promega, Madison, WI, USA) was connected with the FoxO1 3’-UTR sequence containing the binding site of miR-124-5p and the binding site sequence to be mutated. Then, the mutant (MUT) and original (WT) FoxO1 plasmids were constructed and transfected into the cells using Lipofectamine 2000 reagent with miR-124-5p mimics or miR-negative controls (NC). Then, a dual-luciferase reporter gene assay system was used to detect luciferase activity 48 hr after transfection.
significantly compared using Student’s t-test, and the comparison of differences between multiple groups was using one-way analysis of variance (ANOVA). P<0.05 is considered statistically significant.

3. Results

3.1. Tanshinone IIA Pretreatment Attenuates I/R-Induced Brain Injury. The structure of Tanshinone IIA is shown in Figure 1(a). To investigate the therapeutic effect of Tanshinone IIA on I/R-induced brain injury, the cerebral infarction volumes of rats were measured by TTC staining. The results showed that the brain infarct volume was increased in the MCAO group and decreased after treatment with Tanshinone IIA, and the best therapeutic effect was achieved in response to 8-mg/kg Tanshinone IIA (Figure 1(b)). The neuronal size, increased cytoplasmic eosinophils, and visible vacuoles compared to the Sham-operated group (Figures 1(f) and 1(g)). Finally, the effects of Tanshinone IIA on cell proliferation and toxicity in OGD-treated neurons were evaluated in vitro; the MTT assay revealed that Tanshinone IIA altered cell activity (Figure 1(h)), and the LDH assay showed a significant decrease in cell damage after Tanshinone IIA treatment (Figure 1(i)). The best neuronal cell viability and the lowest cell damage were observed in response to 10 μM Tanshinone IIA. In conclusion, Tanshinone IIA pretreatment can reduce I/R-induced brain injury.

3.2. Tanshinone IIA Attenuates the I/R-Induced Inflammatory Response and Neuronal Cell Apoptosis. To ascertain whether the mechanism by which Tanshinone IIA protects neurons affects inflammation and neuronal apoptosis, we examined an in vivo model by TUNEL, ELISA, western blotting, and RT–qPCR. Apoptosis was significantly increased in the MCAO group, and this effect was reversed by Tanshinone IIA (Figure 2(a)). The cytokines in rats were detected by ELISA. The levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α in MCAO group were higher than those in the Sham group. Tanshinone IIA treatment significantly inhibited the production of proinflammatory cytokines (Figure 2(b)–2(d)). Compared with the Sham group, the expression of apoptosis-related proteins Bcl-2 was decreased and the expression of Bax and Cleaved-caspase-3 was increased in the MCAO group, which was significantly reversed after Tanshinone IIA treatment (Figure 2(e)). The results of RT–qPCR were consistent with those of the western blot (Figure 2(f)). These results indicated that Tanshinone IIA could reduce I/R-induced inflammation and neuronal apoptosis in an in vivo model.

3.3. Tanshinone IIA Attenuates the I/R-Induced Inflammatory Response and Neuronal Cell Apoptosis In Vitro. Previously, we determined that the protective effect of Tanshinone IIA on neurons was associated with inflammation and neuronal apoptosis in vivo. Next we examined neuronal cells. The data showed that the expressions of inflammatory factors IL-1β, IL-6, and TNF-α in the OGD group were significantly increased compared with the NC group, after Tanshinone IIA (5, 10, and 15 μM) treatment, the expression of inflammatory factors IL-1β, IL-6, and TNF-α was significantly inhibited (Figure 3(a)–3(c)). These results demonstrate that the treatment with Tanshinone IIA has a robust protective effect against I/R-induced damage to the neuronal cells. Apoptosis was significantly promoted in the OGD group compared with the NC group and was significantly decreased.
FIGURE 1: Tanshinone IIA pretreatment reduces I/R-induced brain injury. (a) Chemical structure of Tanshinone IIA; (b) TTC staining of the brain infarct area; (c) neurological scores; (d) changes in brain infarct volume; (e) wet and dry brain water content; (f) Nissl analysis of surviving neurons in the rat cortex, scale bar = 100 μm; (g) quantification of surviving neurons in the rat cortex; (h) MTT analysis of cell viability; (i) LDH assay of cell damage. "**"P<0.01, "***"P<0.001 compared with the Sham group or NC group; "#"P<0.05, "##"P<0.01, "###"P<0.001 compared with the MCAO group or OGD group.
Tan IIA (4 mg/kg) Sham MCAO Tan IIA (8 mg/kg) Tan IIA (12 mg/kg)

**FIGURE 2**: Continued.
FIGURE 2: Tanshinone IIA reduces the I/R-induced inflammatory response and neuronal cell apoptosis. (a) TUNEL assay of apoptosis in rat cortical cells, scale bar = 100 μm; (b–d) ELISA analysis of IL-1β, IL-6, and TNF-α levels; (e) apoptosis-related proteins were examined by western blot; (f) RT-qPCR was used to analyze the mRNA expression of apoptosis related proteins. ***P<0.001 compared with the Sham group; #P<0.05, ##P<0.01, ###P<0.001, compared with the MCAO group.

FIGURE 3: Continued.
after treatment with Tanshinone IIA (Figures 3(d) and 3(e)). Moreover, the level of apoptosis-related proteins was detected by the western blotting, and the results demonstrated that the OGD group had increased levels of Bax and Cleaved-caspase-3, and decreased levels of Bcl-2, treatment with Tanshinone IIA reversed the protein expression of Bax, Cleaved-caspase-3, and Bcl-2 (Figure 3(f)). The RT–qPCR results were similar to the western blot results (Figure 3(g)). Thus, treatment with Tanshinone IIA markedly attenuated alterations in apoptosis and the I/R-induced inflammatory response.

3.4. Tanshinone IIA Attenuates the I/R-Induced Inflammatory Response and Neuronal Apoptosis by Upregulating miR-124-5p.

Studies have reported that miRNA is involved in signal transduction and regulation of cerebral ischemia–reperfusion injury, which is a potential research object of neuronal injury and repair mechanism. In order to explore the potential molecular mechanism of Tanshinone IIA in alleviating cerebral injury of reperfusion, we detected several miRNAs (miR-9, miR-124-5p, miR-132, and miR-148a-3p) associated with neuron cells [30, 31]. RT–qPCR results showed that the expression of miR-124-5p, miR-132 and miR148a-3p in OGD group was down regulated compared with the NC group, except miR-9, after treatment with the Tanshinone IIA (10 μM), the expression of miR-124-5p was most significantly increased (Figure 4(a)). The abundance of miR-124-5p on neurons may have a vital role in treating the ischemic brain injury, suggesting that miR-124-5p can be used as a marker of reperfusion-induced brain injury. To further validate the expression and the resulting effects of miR-124-5p on reperfusion injury, we evaluated the role of miR-124-5p in neuronal inflammatory response and apoptosis by transfecting miR-124-5p mimic.
FIGURE 4: Continued.
FIGURE 4: Tanshinone IIA attenuates the I/R-induced inflammatory response and neuronal apoptosis by upregulating miR-124-5p. (a) RT-qPCR was used to analyze the mRNA expression of miR-9, miR-124-5p, miR-132 and miR-148a-3p; (b) the transfection efficiency of miR-124-5p was analyzed by RT-qPCR; (c–e) ELISA analysis of cytokine expression; (f, g) flow cytometric analysis of apoptosis; (h) the expressions of apoptosis-related proteins were analyzed by western blot; (i) RT-qPCR was used to analyze the mRNA expression of apoptosis related proteins. *P<0.05, **P<0.01 compared with the NC group; #P<0.05, ##P<0.01 compared with the OGD group.
miR-124-5p inhibitor, and corresponding control (NC mimic, NC inhibitor) in the neuronal cells. First, the level of miR-124-5p increased or decreased significantly after transfection of the miR-124-5p mimic or miR-124-5p inhibitor, respectively (Figure 4(b)). Furthermore, ELISA detected that transfection of miR-124-5p mimic could inhibit the expression of proinflammatory factors IL-1β, IL-6, and TNF-α, but transfection of miR-124-5p inhibitor significantly promoted the expression of proinflammatory factors (Figure 4(c)–4(e)). Flow cytometry was used to detect cell apoptosis. The results showed that compared with the NC group, transfection with miR-124-5p mimic reduced the apoptosis of neuronal cells, while transfection with miR-124-5p inhibitor increased the apoptosis of neuronal cells (Figures 4(f) and 4(g)). The miR-124-5p mimic dramatically increased Bcl-2 expression but decreased Bax and Cleaved-caspase-3 expression, while the miR-124-5p inhibitor had the opposite effects (Figures 4(h) and 4(i)). Taken together, these results suggest that Tanshinone IIA attenuates the I/R-induced inflammatory response and neuronal apoptosis by upregulating miR-124-5p.

3.5. Validation of the Targeted Relationship between miR-124-5p and FoxO1. According to the bioinformatics tool, miR-124-5p was predicted to have targeted binding sites with FoxO1 (Figure 5(a)). This relationship was examined using a dual luciferase reporter gene assay. MiR-124-5p mimic reduced the luciferase activity of FoxO1 wild type plasmid, while miR-124-5p inhibitor promoted the luciferase activity of FoxO1 wild type plasmid. However, miR-124-5p mimic and miR-124-5p inhibitor did not affect the luciferase activity of the mutant plasmid FoxO1 (Figure 5(b)). The miR-124-5p mimic dramatically reduced FoxO1 expression, and the miR-124-5p inhibitor significantly increased FoxO1 levels after OGD treatment (Figures 5(c) and 5(d)). Therefore, miR-124-5p clearly targets and downregulates an FoxO1.

3.6. Inhibiting miR-124-5p or Increasing FoxO1 Eliminated the Inhibitory Effect of Tanshinone IIA on I/R-Induced Brain Injury. To further evaluate the role of miR-124-5p and FoxO1 in mediating Tanshinone IIA on neuronal apoptosis and inflammation. We observed the effect of miR-124-5p antiagomir or FoxO1 overexpression on the efficacy of Tanshinone IIA. TUNEL staining results showed that Tanshinone IIA could effectively reduce the occurrence of apoptosis, but miR-124-5p antiagomir or overexpression of an FoxO1 would attenuate the effect of Tanshinone IIA. Moreover, when miR-124-5p antiagomir acts with overexpression of FoxO1, the inhibitory effect on Tanshinone IIA is more significant (Figure 6(a)). The ELISA results showed that the miR-124-5p antiagomir or FoxO1 overexpression markedly increased proinflammatory cytokines compared with the Tanshinone IIA group. MiR-124-5p antiagomir and FoxO1 overexpression cotreatment further increased inflammatory factor levels in MCAO group (Figure 6(b)–6(d)). Western blot analysis showed that the miR-124-5p antiagomir or FoxO1 overexpression treatment markedly increased the levels of the apoptotic proteins Bax, Cleaved-caspase-3, and reduced the level of Bcl-2 compared with the Tanshinone IIA group (Figure 6(e)). The results of RT–qPCR were consistent with those of western blot (Figure 6(f)). Taken together, Tanshinone IIA can regulate inflammation and apoptosis in the neuronal cells through the miR-124-5p/FoxO1 axis.

4. Discussion

Stroke is the second deadliest disease worldwide, and ischemic stroke is dominant at the time of onset. The sharp reduction in oxygen and nutrients in the ischemic core can mediate metabolic exhaustion, including adenosine triphosphate (ATP) depletion, membrane depolarization, and the overexpression of excitatory amino acids, which will eventually lead to irreversible neuronal damage [32]. Therefore, restoring blood flow to the ischemic location is the best way to reduce neuronal injury. However, thrombolytic reperfusion causes secondary neuronal injury and cellular inflammation through intricate signaling pathways that mediate neuronal death and survival [33]. Since reperfusion-induced neuronal injury and cellular inflammation are supposed to be beneficial, identifying protective remedies against reperfusion injury might be a strategy for the treatment of ischemic stroke. Our findings show that Tanshinone IIA alleviates the symptoms in the cerebral cortex of MCAO rats by reducing brain infarction, edema, neurological deficits, and neuronal apoptosis and inflammation.

Previous reports suggested that Tanshinone IIA, a monomeric chemical compound isolated from Salvia miltiorrhiza, has potential protective effects against cerebral ischemia–reperfusion injury [34, 35]. Tanshinone IIA showed therapeutic effects on both the MCAO/R model and the OGD/R model, as evidenced by the reductions in neurological scores, a reduction in the area of cerebral infarction, and a reduction in brain water content in this study. The therapeutic effect was better when the concentration of Tanshinone IIA was 8 mg/kg and 10 μM in vivo and in vitro, respectively.

The inflammatory response and apoptosis have important roles in reperfusion injury. The extensive activation of proinflammatory factors accelerates the progression of the inflammatory response [36, 37]. Excessive generation of oxygen free radicals creates excessive oxidative stress, which results cell and tissue damage, which is a major cause of acute cerebral ischemic injury [38]. Neuronal apoptosis is associated with the level of Bcl-2 family genes [39]. Caspase is central to apoptosis, and activated caspase-3 is the executor of apoptosis [40]. Caspase-3 guides cascade reactions by cleaving other caspase substrates, which ultimately results in apoptosis. Our results confirmed that Tanshinone IIA inhibited proinflammatory factors, including cytokines, and suppressed apoptosis, which were consistent with the previous studies [39].

As coding factors, miRNAs are widely activated in the central nervous system. These factors are vital regulators of many cellular biological processes, such as cell proliferation, apoptosis, and cell scorching. Microglia-derived exosome miR-124 suppresses neuronal inflammation after traumatic brain injury [41]. In addition, decreased miR-124 levels indicate neuroinflammation in various diseases, such as...
FIGURE 5: Validation of the relationship between miR-124-5p and FoxO1. (a) Target binding site; (b) dual luciferase assay; (c) the expression of FoxO1 was analyzed by RT-qPCR; (d) the expression of FoxO1 was analyzed by western blot. **P < 0.01 compared with the NC-mimic group or NC group; ##P < 0.01, ###P < 0.001 compared with the OGD group.
FIGURE 6: Continued.
experimental autoimmune myelencephalitis [42] and cerebral hemorrhage [43]. A previous study showed that miR-124 injections promoted neuroprotection and functional healing during stroke episodes [22, 41]. In our study, we demonstrated that miR-124-5p was significantly downregulated in the OGD model, and the expression of miR-124-5p was significantly increased after the addition of Tanshinone IIA. Second, when we transfected the miR-124-5p mimic, the levels of proinflammatory factors and apoptosis were inhibited, while miR-124-5p inhibitor treatment enhanced the inflammatory response and increased apoptosis in the neural cells. This finding strongly suggests that Tanshinone IIA can attenuate the inflammatory response and neuronal apoptosis in reperfusion injury by upregulating the level of miR-124-5p.

To further clarify the molecular mechanism of Tanshinone IIA in the treatment of ischemic stroke, we predicted the targeted downstream factor of miR-124-5p by bioinformatics analysis. FoxO1 is expressed in neurons and is regulated by miRNAs [44]. It is exciting to note that miR-124-5p was also shown to target and downregulate an FoxO1 expression. FoxO1 is the first transcription factor 10 discovered in the FOXO family [45], which can participate in the regulation of various physiological and pathological processes of the cells by regulating related genes such as oxidative stress kinase, apoptosis, and autophagy [46, 47]. Meanwhile, it has been reported that FoxO1 can promote the development of cerebral ischemia/reperfusion (CI/R) injury [48]. In addition, studies have shown that artemisinin treatment can alleviate CIRI by mediating SIRT1/FoxO1 signaling pathway [49]. The expression of FoxO1 is upregulated in the brain tissue of CI/R-induced rat models [50]. Our study also showed that FoxO1 was highly expressed in the constructed CI/RI cell model. In addition, inhibition of miR-124-5p or overexpression of FoxO1 successfully weakened the protective effect of Tanshinone IIA on brain injury. These findings suggest that Tanshinone IIA ameliorates apoptosis and the inflammatory response in brain injury through the miR-124-5p/FoxO1 axis.

In conclusion, it was shown that the downregulation of miR-124-5p in MCAO and OGD models promotes FoxO1 expression, which leads to the neuronal cell apoptosis and inflammation. Tanshinone IIA alleviates ischemic–reperfusion injury via the miR-124-5p/FoxO1 axis, providing a new therapeutic target for ischemic stroke. Furthermore, our study has the limitation of not detecting changes in miR-124-5p and FoxO1 expression before and after Tanshinone IIA treatment in the clinical samples. In the next study, we will examine clinical samples to further verify the molecular indicators of this mechanism.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Wenbing Su and Meifen Lv contributed in the conceptualization; Wenbing Su, Meifen Lv, and Yinghong He contributed in the methodology; Dayu Wang and Xiuying Zhang...
contributed in the software; Hui Han and Yu Zhang contributed in the validation; Wenbing Su, Meifen Lv, and Shaokun Lv contributed in the formal analysis; Shaokun Lv, Liqing Yao, Wenbing Su, and Meifen Lv contributed in the investigation; Liqing Yao and Shaokun Lv contributed in the resources; Wenbing Su, Meifen Lv, Yinghong He, and Dayu Wang contributed in the data curation; Wenbing Su, Meifen Lv, Xiuying Zhang, and Hui Han contributed in the writing—original draft preparation; Wenbing Su, Meifen Lv, and Shaokun Lv contributed in the writing—review and editing; Meifen Lv and Yu Zhang contributed in the visualization; Shaokun Lv contributed in the supervision; Liqing Yao and Shaokun Lv contributed in the funding acquisition. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

This research was supported by the Yunnan Key Clinical Specialty Construction Project (project number: 2018-04).

References


